Celyad teams-up with Institut Curie to advance its immuno-oncology program
pharmafile | March 22, 2016 | News story | Manufacturing and Production, Research and Development | Cancer Immunotherapy, Celyad, Institut Curie, cellular immunotherapies
Celyad (Nasdaq: CYAD) on Tuesday said it has partnered with Institut Curie to develop its NKR-T pipeline in cellular immunotherapies for cancer.
Christian Homsy, chief executive of Celyad, says: “Our NKR-T program has a great potential for cancer treatment and we want to develop it according the highest standards. This collaboration shows that our technology is raising the interest of the top scientific community.”
No financial details were disclosed.
The company is collaborating with Inserm Cancer and Immunity unit of Institut Curie to expand Celyad’s immuno-oncology pipeline. The partnership will involve Institut Curie’s preclinical and clinical know-how in cancer biology and immunology, and Celyad’s cell therapy and cell manufacturing capabilities.
At Institut Curie, the collaboration will be under the supervision of Sebastian Amigorena, head of the future Center for Cancer Immunotherapy.
Sebastian Amigorena, head of the cancer and immunity unit of the Institut Curie, says: “Our collaboration with Celyad is particularly timely in the context of the future launching of the Center for Cancer Immunotherapy of Institut Curie coming in autumn 2016. Celyad is well positioned to become a global leader in cell therapies for cancer treatment and we are looking forward to strengthening our expertise in this field. This collaboration could lead to a real clinical benefit for cancer patients.”
Anjali Shukla
Related Content
Male birth control drug may hold promise for treating lung cancer, Chinese study finds
A drug for male birth control may hold promise for treating lung cancer patients when …
J&J sign deal with Scottish firm AdoRx to develop novel lung cancer treatments
Edinburgh-based drug discovery firm AdoRx therapeutics has signed a deal with US healthcare conglomerate Johnson …
Merck says US FDA to review its Keytruda for head & neck cancer
The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application …
